Alector and Johnson & Johnson to Collaborate over Alzheimer’s Disease Antibody Drug

Alector, a San Francisco based biotech start-up, will join forces with Johnson & Johnson’s (J&J) Innovation Center to conduct research on new antibody-based therapies for Alzheimer’s disease (AD). Alector is designing monoclonal antibodies against key targets associated with AD, using current scientific understanding of the sporadic form of the disease. To achieve this goal, Alector is leveraging the expertise of Adimab, the top yeast display antibody company. J&J will be fund the research, hoping for better performance than their own bapineuzumab, which failed to outperform the placebo in treating AD.

Alector, a San Francisco based biotech start-up, will join forces with Johnson & Johnson’s (J&J) Innovation Center to conduct research on new antibody-based therapies for Alzheimer’s disease (AD). Alector is designing monoclonal antibodies against key targets associated with AD, using current scientific understanding of the sporadic form of the disease. To achieve this goal, Alector is leveraging the expertise of Adimab, the top yeast display antibody company. J&J will be fund the research, hoping for better performance than their own bapineuzumab, which failed to outperform the placebo in treating AD.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail